Hyperlipidemia as a Risk Factor for Cardiovascular Disease

Primary Care - Clinics in Office Practice

Volumn 40, Issue 1, 2013, Pages 195-211

  Nelson, Robert H ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Cardiometabolic risk; CVD risk factors; Dyslipidemia; Hypercholesterolemia; Hypertriglyceridemia

Indexed keywords

ATORVASTATIN; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTHRALGIA; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CEREBROTENDINOUS XANTHOMATOSIS; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG TARGETING; DYSPEPSIA; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FAMILIAL HYPOBETALIPOPROTEINEMIA; GALLSTONE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPOLYSIS; LIVER TOXICITY; METABOLIC DISORDER; MULTIFACTORIAL INHERITANCE; MYOPATHY; PANCREATITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SINUSITIS; SITOSTEROLEMIA; STEROL METABOLISM; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; MASS SCREENING; RISK ASSESSMENT; RISK FACTORS;

EID: 84873586706     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2012.11.003     Document Type: Review

References (52)

1. National Ambulatory Medical Care Survey: 2009 Summary Tables. In: National Ambulatory Medical Care Survey: 2009 Summary Tables, The Ambulatory and Hospital Care Statistics Branch of the Centers for Disease Control and Prevention's National Center for Health Statistics, 2009, p. Table 16. Presence of selected chronic conditions at office visits, by patient age and sex: United States 2009. Available at: Accessed September 5, 2012. http://www.cdc.gov/nchs/data/ahcd/namcs_summary/2009_namcs_web_tables.pdf.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
3. Murphy S.L., Xu J.Q., Kochanek K.D. Deaths: preliminary data for 2010. National vital statistics reports, Table B 2012, National Center for Health Statistics, Hyattsville (MD).
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
5. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
6. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J Lipid Res 2004, 45:1583-1593.
7. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res 2005, 46:179-190.
8. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J Lipid Res 2005, 46:2037-2051.
9. Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it-almost. J Lipid Res 2006, 47:1-14.
10. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res 2006, 47:1339-1351.
11. US Preventive Services Task Force. Screening for lipid disorders in adults. 2008. Available at: Accessed August 29, 2012. http://www.uspreventiveservicestaskforce.org/uspstf/uspschol.htm.
12. American Heart Association. Public cholesterol screening. 2011. Available at: Accessed September 5, 2012. http://www.heart.org/HEARTORG/Conditions/Cholesterol/SymptomsDiagnosisMonitoringofHighCholesterol/Public-Cholesterol-Screening-Adults-and-Children_UCM_305617_Article.jsp.
13. Semenkovich C.F., Goldberg A.C., Goldberg I.J. Disorders of lipid metabolism. Williams textbook of endocrinology 2011, 1655. W.B. Saunders, Philadelphia. 12th edition. S. Melmed, K.S. Polonsky, P.R. Larsen (Eds.).
14. Aberg J.A. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am 2009, 38:207-222.
15. Chapter 3.3 Assessment of cardiovascular risk. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease 2008, 49-54. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London. A. Cooper, L. Nherera, N. Calvert (Eds.).
16. Peters S.A., den Ruijter H.M., Bots M.L., et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012, 98:177-184.
17. Yeboah J., McClelland R.L., Polonsky T.S., et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012, 308:788-795.
18. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012, 307:1302-1309.
19. Di Angelantonio E., Gao P., Pennells L., et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012, 307:2499-2506.
20. Grundy S.M. Use of emerging lipoprotein risk factors in assessment of cardiovascular risk. JAMA 2012, 307:2540-2542.
21. Balk E.M., Lau J., Goudas L.C., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003, 139:670-682.
22. ATP-III at-a-glance: quick desk reference 2001. Available at: Accessed September 5, 2012. http://www.nhlbi.nih.gov/guidelines/cholesterol/dskref.htm.
23. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005, 96:556-563.
24. Centers for Disease Control and Prevention QuickStats: average total cholesterol level among men and women 2009, Department of Health and Human Services, Atlanta (GA), p. 1045.
25. Curioni C.C., Lourenco P.M. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005, 29:1168-1174.
26. Makris A., Foster G.D. Dietary approaches to the treatment of obesity. Psychiatr Clin North Am 2011, 34:813-827.
27. Hemphill L.C. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol 2010, 4:346-349.
28. Oosterveer D.M., Versmissen J., Yazdanpanah M., et al. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. Atherosclerosis 2009, 207:311-317.
29. Sharma M., Ansari M.T., Abou-Setta A.M., et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009, 151:622-630.
30. Stevinson C., Pittler M.H., Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 2000, 133:420-429.
31. Wider B., Pittler M.H., Thompson-Coon J., et al. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev 2009, (4). CD003335.
32. Nies L.K., Cymbala A.A., Kasten S.L., et al. Complementary and alternative therapies for the management of dyslipidemia. Ann Pharmacother 2006, 40:1984-1992.
33. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
34. Jonas D., Van Scoyoc E., Gerrald K., et al. Drug class review: newer diabetes medications, TZDs, and combinations: final original report 2011, [Internet], Oregon Health & Science University, Portland (OR), Available at:, Accessed August 31, 2012. http://www.ncbi.nlm.nih.gov/books/NBK54209/.
35. Cannon C.P., Steinberg B.A., Murphy S.A., et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438-445.
36. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
37. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
38. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
39. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
40. Preiss D., Tikkanen M.J., Welsh P., et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012, 308:804-811.
41. Sharma M., Ansari M.T., Soares-Weiser K., et al. Comparative effectiveness of lipid-modifying agents. Comparative effectiveness review 2009, ES1-ES14. Prepared by the University of Ottawa Evidence-based Practice Center under contract No. 290-02-0021, Agency for Healthcare Research and Quality, Rockville (MD), Available at:, Accessed September 5, 2012. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.
42. Conly J., Clement F., Tonelli M., et al. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ 2011, 183:E1180-E1188.
43. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
44. Ghosh R.K., Ghosh S.M. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update. Curr Clin Pharmacol 2012, 7:102-110.
45. Voight B.F., Peloso G.M., Orho-Melander M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
46. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
47. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
48. Gregson J., Stirnadel-Farrant H.A., Doobaree I.U., et al. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature. Atherosclerosis 2012, 225:11-21.
49. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
50. Teramoto T. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C. Expert Opin Pharmacother 2012, 13:859-865.
51. Maruyama T., Takada M., Nishibori Y., et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011, 75:1951-1959.
52. Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.